Furthermore, we validated the anti-tumor effects of down-regulation of Gli1 in gastric cancer cells and in heterologous subcutaneous caner mice, trying to identify a novel target for therapeutic intervention, especially in HER2-targeted therapy-resistant gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.